ReviewFrontiers in endocrinology2026
Venous thromboembolism in Cushing syndrome: current evidence and a practical thromboprophylaxis algorithm.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cushing syndrome (CS) is a rare endocrine disorder associated with a markedly increased risk of venous thromboembolism (VTE). Chronic hypercortisolism induces a prothrombotic state through activation of coagulation pathways, impaired fibrinolysis, and endothelial dysfunction. VTE represents a major source of morbidity and mortality in this population, yet optimal strategies for prevention and treatment remain insufficiently standardized. To summarize current evidence on the epidemiology, pathophysiology, risk factors, prevention, and treatment of VTE in patients with endogenous CS and to propose a practical thromboprophylaxis approach. A narrative review of the literature was conducted using MEDLINE/PubMed, Scopus, and Embase databases. Observational studies, registry data, systematic reviews, and expert consensus statements addressing VTE in CS were analyzed, with particular attention to peri-operative risk and persistence of hypercoagulability after remission. Patients with CS have a 10-20-fold higher risk of VTE compared with the general population. The peri-operative period, especially after TSS or adrenalectomy, represents the highest-risk phase, although increased thrombotic risk may persist for 3-6 months after biochemical remission. Key mechanisms include elevated factor VIII, von Willebrand factor, plasminogen activator inhibitor-1, increased thrombin generation, and endothelial dysfunction. Recent evidence from the ERCUSYN registry and the 2025 Delphi consensus supports early and extended thromboprophylaxis. Current expert consensus supports low-molecular-weight heparin as the preferred peri-operative pharmacological agent, whereas direct oral anticoagulants may be considered in selected patients during long-term management. CS should be regarded as a persistent prothrombotic condition in which early and, when appropriate, extended thromboprophylaxis should be considered following individualized assessment of thrombotic and bleeding risk. Prospective studies are needed to develop evidence-based, individualized prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.